MX2017004037A - Derivados de acido boronico. - Google Patents
Derivados de acido boronico.Info
- Publication number
- MX2017004037A MX2017004037A MX2017004037A MX2017004037A MX2017004037A MX 2017004037 A MX2017004037 A MX 2017004037A MX 2017004037 A MX2017004037 A MX 2017004037A MX 2017004037 A MX2017004037 A MX 2017004037A MX 2017004037 A MX2017004037 A MX 2017004037A
- Authority
- MX
- Mexico
- Prior art keywords
- acid derivatives
- boronic acid
- lmp7
- inhibitors
- employed
- Prior art date
Links
- 150000001642 boronic acid derivatives Chemical class 0.000 title 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 abstract 1
- 101001136986 Homo sapiens Proteasome subunit beta type-8 Proteins 0.000 abstract 1
- 102100035760 Proteasome subunit beta type-8 Human genes 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14003390 | 2014-10-01 | ||
| PCT/EP2015/001930 WO2016050355A1 (en) | 2014-10-01 | 2015-10-01 | Boronic acid derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017004037A true MX2017004037A (es) | 2017-07-04 |
Family
ID=51690787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017004037A MX2017004037A (es) | 2014-10-01 | 2015-10-01 | Derivados de acido boronico. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10640520B2 (enExample) |
| EP (1) | EP3201205B1 (enExample) |
| JP (1) | JP6835710B2 (enExample) |
| KR (1) | KR20170066506A (enExample) |
| CN (1) | CN107108660B (enExample) |
| AU (1) | AU2015327411B2 (enExample) |
| BR (1) | BR112017006368A2 (enExample) |
| CA (1) | CA2963186A1 (enExample) |
| ES (1) | ES2811273T3 (enExample) |
| IL (1) | IL251300A0 (enExample) |
| MX (1) | MX2017004037A (enExample) |
| RU (1) | RU2017115193A (enExample) |
| SG (1) | SG11201702625PA (enExample) |
| WO (1) | WO2016050355A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ730981A (en) | 2014-10-01 | 2024-01-26 | Merck Patent Gmbh | Boronic acid derivatives |
| JP6835711B2 (ja) | 2014-10-01 | 2021-02-24 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | ボロン酸誘導体 |
| EP3201208B1 (en) | 2014-10-01 | 2021-03-24 | Merck Patent GmbH | Boronic acid derivatives |
| JP7289828B2 (ja) * | 2017-08-23 | 2023-06-12 | ケザール ライフ サイエンシズ | 自己免疫疾患の治療における免疫プロテアソーム阻害剤および免疫抑制剤 |
| AU2018321118B2 (en) * | 2017-08-24 | 2023-06-15 | Merck Patent Gmbh | Boronic acid derivatives |
| CA3107377A1 (en) | 2018-07-26 | 2020-01-30 | Merck Patent Gmbh | Boronic acid derivatives |
| BR112021006339A2 (pt) | 2018-10-04 | 2021-07-06 | Kezar Life Sciences | formulação de inibidor de imunoproteassoma |
| CN113135943A (zh) * | 2020-01-19 | 2021-07-20 | 首药控股(北京)有限公司 | 硼酸衍生物 |
| CN113135944A (zh) * | 2020-01-19 | 2021-07-20 | 首药控股(北京)有限公司 | 硼酸衍生物 |
| JP7568432B2 (ja) * | 2020-07-01 | 2024-10-16 | リファインホールディングス株式会社 | モルホリン誘導体およびその製造方法 |
| CN114075227B (zh) * | 2020-08-19 | 2023-07-04 | 北京嵩润医药科技有限责任公司 | 吡唑硼酸类化合物、包含其的药物组合物及它们的用途 |
| US20250340577A1 (en) * | 2021-03-02 | 2025-11-06 | Case Western Reserve University | Beta-lactomase inhibitors and uses thereof |
| CN116940580A (zh) * | 2021-03-05 | 2023-10-24 | Ａｇｃ株式会社 | 化合物、化合物的制造方法及表面处理剂的制造方法 |
| WO2023006863A1 (en) | 2021-07-29 | 2023-02-02 | Merck Patent Gmbh | Novel crystalline forms of [(1r)-2-(1-benzofuran-3-yl)-1-{[(1s,2r,4r)-7- oxabicyclo[2.2.1]heptan-2-yl]formamido}ethyl]boronic acid, adducts thereof, and processes to obtain |
| WO2023232830A1 (en) | 2022-06-02 | 2023-12-07 | Merck Patent Gmbh | Boronic acid adducts |
| CN120736500A (zh) * | 2025-08-25 | 2025-10-03 | 安徽得壹能源科技有限公司 | 一种磷酸铁锂正极材料、其制备方法及电池 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5563127A (en) * | 1993-03-24 | 1996-10-08 | The Dupont Merck Pharmaceutical Company | Boronic acid and ester inhibitors of thrombin |
| IL111175A0 (en) * | 1993-10-07 | 1994-12-29 | Du Pont Merck Pharma | Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them |
| US6060462A (en) * | 1993-10-20 | 2000-05-09 | Dupont Pharmaceuticals Company | Electrophilic peptide analogs as inhibitors of trypsin-like enzymes |
| FR2758329B1 (fr) * | 1997-01-16 | 1999-02-12 | Synthelabo | Derives d'imidazole-4-butane boronique, leur preparation et leur utilisation en therapeutique |
| US20100120715A1 (en) * | 2007-11-13 | 2010-05-13 | Burns Christopher J | Beta-lactamase inhibitors |
| WO2009064413A1 (en) * | 2007-11-13 | 2009-05-22 | Protez Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| AR075090A1 (es) * | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden. |
| CN104321060B (zh) * | 2011-12-22 | 2018-08-07 | 阿雷斯贸易股份有限公司 | α-氨基硼酸衍生物，选择性免疫蛋白酶体抑制剂 |
| EP2970340B1 (en) * | 2013-03-14 | 2020-02-12 | Venatorx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| NZ730981A (en) | 2014-10-01 | 2024-01-26 | Merck Patent Gmbh | Boronic acid derivatives |
| EP3201208B1 (en) | 2014-10-01 | 2021-03-24 | Merck Patent GmbH | Boronic acid derivatives |
| JP6835711B2 (ja) | 2014-10-01 | 2021-02-24 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | ボロン酸誘導体 |
-
2015
- 2015-10-01 AU AU2015327411A patent/AU2015327411B2/en not_active Ceased
- 2015-10-01 RU RU2017115193A patent/RU2017115193A/ru not_active Application Discontinuation
- 2015-10-01 MX MX2017004037A patent/MX2017004037A/es unknown
- 2015-10-01 SG SG11201702625PA patent/SG11201702625PA/en unknown
- 2015-10-01 WO PCT/EP2015/001930 patent/WO2016050355A1/en not_active Ceased
- 2015-10-01 KR KR1020177011627A patent/KR20170066506A/ko not_active Withdrawn
- 2015-10-01 ES ES15775380T patent/ES2811273T3/es active Active
- 2015-10-01 EP EP15775380.7A patent/EP3201205B1/en active Active
- 2015-10-01 BR BR112017006368A patent/BR112017006368A2/pt not_active IP Right Cessation
- 2015-10-01 JP JP2017518069A patent/JP6835710B2/ja not_active Expired - Fee Related
- 2015-10-01 CA CA2963186A patent/CA2963186A1/en active Pending
- 2015-10-01 CN CN201580053424.7A patent/CN107108660B/zh not_active Expired - Fee Related
- 2015-10-01 US US15/516,420 patent/US10640520B2/en active Active
-
2017
- 2017-03-21 IL IL251300A patent/IL251300A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP6835710B2 (ja) | 2021-02-24 |
| RU2017115193A3 (enExample) | 2019-02-08 |
| AU2015327411A1 (en) | 2017-05-18 |
| US10640520B2 (en) | 2020-05-05 |
| IL251300A0 (en) | 2017-05-29 |
| WO2016050355A1 (en) | 2016-04-07 |
| CN107108660A (zh) | 2017-08-29 |
| AU2015327411B2 (en) | 2020-01-02 |
| US20180179231A1 (en) | 2018-06-28 |
| SG11201702625PA (en) | 2017-04-27 |
| EP3201205B1 (en) | 2020-05-13 |
| KR20170066506A (ko) | 2017-06-14 |
| CN107108660B (zh) | 2020-09-15 |
| BR112017006368A2 (pt) | 2017-12-19 |
| JP2018502049A (ja) | 2018-01-25 |
| EP3201205A1 (en) | 2017-08-09 |
| CA2963186A1 (en) | 2016-04-07 |
| ES2811273T3 (es) | 2021-03-11 |
| RU2017115193A (ru) | 2018-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017500293A1 (en) | Boronic acid derivatives | |
| MX2017004037A (es) | Derivados de acido boronico. | |
| MX2017004043A (es) | Derivados de acido boronico. | |
| MX2017004046A (es) | Derivados de acido boronico. | |
| IL259787A (en) | Mutant isocitrate dehydrogenase 1 (idh1) suppressor for the treatment of malignancies | |
| PH12017500509A1 (en) | Benzyl substituted indazoles as bub1 inhibitors | |
| NZ724691A (en) | Quinoline derivatives as smo inhibitors | |
| MX2016012829A (es) | Inhibidores de biaril cinasa. | |
| MX381417B (es) | Inhibidores de glucosidasa. | |
| PH12017500745A1 (en) | Bromodomain inhibitors | |
| TW201613886A (en) | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones | |
| AU2015299431B2 (en) | Pyrrolidinone derivatives as metAP-2 inhibitors | |
| MX2016002924A (es) | Inhibidores de cinasa a base de eter arilico. | |
| MX2015009818A (es) | Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerosis multiple. | |
| MX2016009355A (es) | Inhibidores de aril lactama cinasa. | |
| PH12017501071A1 (en) | Dihydropyrimidin-2-one compounds and medical use thereof | |
| MA39824A (fr) | Composés azole amido-substitués | |
| EA201790687A1 (ru) | Хинолинкарбоксамиды для применения в лечении множественной миеломы | |
| EA201791099A1 (ru) | Хинолин карбоксамиды для применения в лечении лейкоза | |
| TN2016000208A1 (en) | Novel compound for treatment of severe hypoglycemia. | |
| PH12016501182A1 (en) | Novel compound for treatment of severe hypoglycemia | |
| PH12016501184A1 (en) | Novel compound for treatment of severe hypoglycemia | |
| TW201613928A (en) | Vinyl compounds as inhibitors for FGFR and VEGFR | |
| UA95450U (uk) | 2-(6-етокси-2-метилхінолін-4-ілтіо)-сукцинатна кислота, що проявляє антиоксидантну активність |